SENSEX
NIFTY 50
Hang Seng
Taiwan Weighted
MCX GOLD DEC 05
MCX SILVER DEC 05
USD/INR
EUR/INR80.0630

SENSEX
NIFTY 50
NIFTY MIDCAP 100
S&P BSE MIDCAP
Hang Seng
Taiwan Weighted
DAX
Nasdaq
MCX GOLD DEC 05
MCX SILVER DEC 05
MCX CRUDEOIL NOV 16
MCX NATURALGAS OCT 26
USD/INR
EUR/INR
GBP/INR
JPY/INR

Closing Bell: Sensex ends 244 points lower, Nifty below 14,300 dragged by IT stocks; broader markets outperform

Asian shares at highest since early March, weak dollar boosts commodities

Oil holds near one-month highs as demand forecasts raised

Rupee rises 23 paise to 74.64 against US dollar in early trade

Expect things to normalise as COVID-19 vaccinations ramp up, says Lupin's Vinita Gupta

Updated : March 08, 2021 03:06 PM IST

On Women's Day, CNBC-TV18 is speaking to a host of women from India Inc to get a sense of their journey to the top, the challenges, the hurdles and the victories. Lupin chief executive officer (CEO) Vinita Gupta shared her views on COVID-19, business, earnings and more.

“There is still a very strong number of cases in particular in the US. From a lockdown point, some states have more of a lockdown than others. I wouldn’t say that things are back to normal or getting back to normal, we hope they would be in the second half of this year with vaccinations ramping up over the next couple of months,” she told CNBC-TV18.

Maintaining supply continuity was essential through the pandemic, Gupta added.

“It was essential for us to keep supply continuity which was hugely challenged through the pandemic. So our team worked very hard to ensure that we continue the supply of medicines.”

“I believe we are very well set to grow our business in the fiscal year 2022,” she mentioned.

On the US market, Gupta said, “There are a lot of exciting opportunities ahead at this point. It has been a very exciting journey for our company over the last 20 years. All of the investments that we have made to drive our generics business, our affordable medicines business to the next level with all our complex generic platform investments are starting to come to market now, are starting to get validated now.”

“In the last five-six years we have invested into platforms like inhalations, biosimilars, injectables, women’s health products and in each area we have made tremendous progress,” she added.

The company has received approval for Albuterol in 2020.

“We are ramping it up right now. We have multiple other applications pending at the agency on the inhalation front, so in the next couple of years we see inhalation driving generic business very nicely,” she said.

In terms of the pipeline, the company has a number of products filed. “Five products in the near-term, in the next two years. The fiscal year 2023 will be a significant year for us as we intend to launch products like Albuterol, Fostair in Europe, Spiriva in the year 2023,” she mentioned.

According to Gupta, the generic industry saw intense price erosion 3-4 years ago because of additional consolidation in the marketplace at the customer end.

“However, in the last year or so, we started to see things normalise. We still continue to have pricing pressure but low single-digit, mid-single-digit price erosion and we expect that in the year to come. Our effort has been to continuously work to evolve our pipeline, be ahead of the game with our pipeline,” she pointed out.

On India business, she said, “India business is depending on the lockdown situation and the sentiment in the marketplace. In our portfolio, we have acute care products as well as chronic care products. Chronic care products have done extremely well. Acute care products struggled in India overall.”

“We continue to work very hard in enhancing or remediating the issues across the different sites, learning from every inspection from every site and sharing across all our networks the best practices,” she mentioned.

For the full interview, watch the video

Published : March 08, 2021 03:06 PM IST

You May Also Like

Apple Event 2021 highlights: 11-in and 12.9-in iPad Pros, 24-in M1 iMac, Purple iPhone 12 launched

Apple Event 2021 highlights: 11-in and 12.9-in iPad Pros, 24-in M1 iMac, Purple iPhone 12 launched

Creators throng to Apple's new M1 Macs as they see gains in productivity

Creators throng to Apple's new M1 Macs as they see gains in productivity

In Pics | COVID-19 data highlights for April 20: 2.59 lakh new cases, total death toll climbs to 1.80 lakh

In Pics | COVID-19 data highlights for April 20: 2.59 lakh new cases, total death toll climbs to 1.80 lakh

Trending on CNBC-TV18

Live TV

recommended for you